CytomX Therapeutics, Inc. - Common Stock (CTMX)
CUSIP: 23284F105
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 169,491,059
- Total 13F shares
- 133,305,109
- Share change
- +88,021,897
- Total reported value
- $302,602,132
- Put/Call ratio
- 40%
- Price per share
- $2.27
- Number of holders
- 82
- Value change
- +$213,797,054
- Number of buys
- 55
- Number of sells
- 29
Quarterly Holders Quick Answers
What is CUSIP 23284F105?
CUSIP 23284F105 identifies CTMX - CytomX Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 23284F105:
Top shareholders of CTMX - CytomX Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Longitude Capital Partners V, LLC |
13D/G
|
— |
7.3%
|
11,538,461
|
$8,192,307 | $0 | 13 May 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
4%
|
6,717,825
|
$4,271,193 | — | 31 Mar 2025 | |
| BVF INC/IL |
13F
|
Company |
3.1%
|
5,228,461
|
$3,324,256 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3%
|
5,117,376
|
$3,254,651 | — | 31 Mar 2025 | |
| Prosight Management, LP |
13F
|
Company |
2.3%
|
3,930,008
|
$2,498,699 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
1.9%
|
3,234,035
|
$2,053,000 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.7%
|
2,826,276
|
$1,796,946 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.6%
|
2,650,000
|
$1,684,870 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.98%
|
1,657,306
|
$1,053,715 | — | 31 Mar 2025 | |
| Laurion Capital Management LP |
13F
|
Company |
0.76%
|
1,293,686
|
$822,526 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.69%
|
1,166,384
|
$741,588 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.68%
|
1,156,000
|
$734,985 | — | 31 Mar 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
0.59%
|
1,000,000
|
$635,800 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.51%
|
857,958
|
$545,625 | — | 31 Mar 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.45%
|
762,930
|
$485,000 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.44%
|
746,788
|
$474,957 | — | 31 Mar 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.42%
|
711,454
|
$452,342 | — | 31 Mar 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.4%
|
686,208
|
$436,291 | — | 31 Mar 2025 | |
| Congress Park Capital LLC |
13F
|
Company |
0.4%
|
673,686
|
$428,330 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.35%
|
589,332
|
$374,696 | — | 31 Mar 2025 | |
| SEI INVESTMENTS CO |
13F
|
Company |
0.29%
|
487,902
|
$310,208 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.27%
|
463,854
|
$294,547 | — | 31 Mar 2025 | |
| Seven Fleet Partners LP |
13D/G
|
— |
0.2%
|
377,161
|
$267,784 | $0 | 13 May 2025 | |
| Formidable Asset Management, LLC |
13F
|
Company |
0.21%
|
353,840
|
$224,971 | — | 31 Mar 2025 | |
| Tidal Investments LLC |
13F
|
Company |
0.21%
|
353,840
|
$224,971 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.19%
|
320,043
|
$203,483 | — | 31 Mar 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.18%
|
306,624
|
$194,952 | — | 31 Mar 2025 | |
| Jeffrey B. Landau |
3/4/5
|
Chief Business Officer |
—
mixed-class rows
|
266,736
mixed-class rows
|
$155,772 | — | 20 Aug 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.14%
|
241,980
|
$153,851 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.09%
|
150,632
|
$95,772 | — | 31 Mar 2025 | |
| Aspire Growth Partners LLC |
13F
|
Company |
0.05%
|
92,254
|
$88,610 | — | 31 Mar 2025 | |
| Amy C. Peterson |
3/4/5
|
EVP, Chief Development Officer |
—
class O/S missing
|
58,433
|
$80,678 | — | 16 Mar 2023 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.07%
|
116,475
|
$74,055 | — | 31 Mar 2025 | |
| Lloyd A. Rowland |
3/4/5
|
General Counsel |
—
class O/S missing
|
120,594
|
$72,236 | — | 18 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.06%
|
108,311
|
$68,864 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.06%
|
105,294
|
$66,946 | — | 31 Mar 2025 | |
| Forefront Analytics, LLC |
13F
|
Company |
0.06%
|
100,070
|
$63,141 | — | 31 Mar 2025 | |
| Universal- Beteiligungs- und Servicegesellschaft mbH |
13F
|
Individual |
0.06%
|
97,123
|
$61,751 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.05%
|
85,539
|
$54,746 | — | 31 Mar 2025 | |
| Carlos Campoy |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
38,224
|
$52,776 | — | 16 Mar 2023 | |
| PRUDENTIAL FINANCIAL INC |
13F
|
Company |
0.05%
|
81,500
|
$51,818 | — | 31 Mar 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
0.04%
|
75,000
|
$47,685 | — | 31 Mar 2025 | |
| Alison L. Hannah |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
31,898
|
$44,042 | — | 19 Jul 2022 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.04%
|
61,719
|
$39,241 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.04%
|
60,584
|
$38,519 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.03%
|
54,808
|
$34,847 | — | 31 Mar 2025 | |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
|
Company |
0.03%
|
54,243
|
$34,000 | — | 31 Mar 2025 | |
| Miller Financial Services LLC |
13F
|
Company |
0.03%
|
51,000
|
$32,426 | — | 31 Mar 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.03%
|
47,036
|
$29,905 | — | 31 Mar 2025 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.03%
|
44,576
|
$28,340 | — | 31 Mar 2025 |
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock (CTMX) as of Q2 2025
As of 30 Jun 2025,
CytomX Therapeutics, Inc. - Common Stock (CTMX) was held by
82 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
133,305,109 shares.
The largest 10 holders included
VR ADVISER, LLC, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, FMR LLC, ORBIMED ADVISORS LLC, Point72 Asset Management, L.P., Commodore Capital LP, PERCEPTIVE ADVISORS LLC, Vivo Capital, LLC, and FRANKLIN RESOURCES INC.
This page lists
83
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
63
Q2 2025 holders
82
Holder diff
19
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.